VJHemOnc is committed to improving our service to you

Share this video  

VJHemOnc is committed to improving our service to you

COSTEM 2021 | Outcomes of older myelofibrosis patients who receive allogeneic transplantation

Juan Carlos Hernández-Boluda, MD, PhD, Hospital Clínico Universitario Valencia, Valencia, Spain, comments on the findings of a retrospective study investigating the outcomes of older patients with myelofibrosis who undergo allogeneic transplantation. Dr Hernández-Boluda reports that patients who received transplant had a 5-year overall survival rate of around 40%, and that in the long-term outcomes were better for patients who received transplant compared to conventional treatment, although there is increased mortality in the first couple of years post-transplant. Dr Hernández-Boluda also comments on sex-based differences in outcomes. This interview took place at the 6th Congress on Controversies in Stem Cell Transplantation and Cellular Therapies (COSTEM), which took place virtually.

Disclosures

Juan Carlos Hernández-Boluda, MD, PhD, has received advisory honoraria from BMS and AOP Pharma; travel support from Incyte and Pfizer; and speaker fees from Pfizer, Novartis and Incyte.

Sign-up for our Newsletter!

Keep up to date with all the latest news with our monthly newsletter